The company continues to build evidence for the added sensitivity offered by its urine- and blood-based liquid biopsy approach in an effort to engage clinicians.
The firm's reagents and disposables business was the biggest gainer, with a 12 percent revenue increase in the quarter.
The firm saw decreases in its core diagnostics business that were offset in part by revenues from newly-acquired Magellan Diagnostics.
The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.
Sales of the firm's infectious disease and women's health products were credited with driving the year-over-year increase in revenues.
In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.
South African researchers uncover bone cancer in an ancient hominin ancestor.
English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.
Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.